Effect of Xuefu Zhuyu Capsule (血府逐瘀胶囊) on the symptoms and signs and health-related quality of life in the unstable angina patients with blood-stasis syndrome after percutaneous coronary intervention: A Randomized controlled trial

Fu-yong Chu; Jie Wang; Kui-wu Yao; Zhi-zhong Li

doi:10.1007/s11655-010-9999-9

Your Location：

Home >

Browse articles >

Effect of Xuefu Zhuyu Capsule (血府逐瘀胶囊) on the symptoms and signs and health-related quality of life in the unstable angina patients with blood-stasis syndrome after percutaneous coronary intervention: A Randomized controlled trial

OriginalPaper | Updated：2021-08-27

- Effect of Xuefu Zhuyu Capsule (血府逐瘀胶囊) on the symptoms and signs and health-related quality of life in the unstable angina patients with blood-stasis syndrome after percutaneous coronary intervention: A Randomized controlled trial
- Effect of Xuefu Zhuyu Capsule (血府逐瘀胶囊) on the symptoms and signs and health-related quality of life in the unstable angina patients with blood-stasis syndrome after percutaneous coronary intervention: A Randomized controlled trial
- 中国结合医学杂志（英文版） 2010年16卷第5期页码：399-405
- Affiliations：
  
  1. Department of Cardiology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences,Beijing,China
  2. Rescue Center of Emergency, Anzhen Hospital, China Capital University of Medical Science,Beijing,China,100029
- Author bio：
- Funds：
  
  Supported by the National Natural Science Foundation of China (No. 90709048) Clinical Trials.;Gov Identifier: NCT00817024
- DOI：10.1007/s11655-010-9999-9
  中图分类号：
- 纸质出版日期：2010，
  
  网络出版日期：2010-6-10，
Scan for full text
Chu, Fy., Wang, J., Yao, Kw. et al. Effect of Xuefu Zhuyu Capsule (血府逐瘀胶囊) on the symptoms and signs and health-related quality of life in the unstable angina patients with blood-stasis syndrome after percutaneous coronary intervention: A Randomized controlled trial., Chin. J. Integr. Med. 16, 399–405 (2010). https://doi.org/10.1007/s11655-010-9999-9

Fu-yong Chu, Jie Wang, Kui-wu Yao, et al. Effect of Xuefu Zhuyu Capsule (血府逐瘀胶囊) on the symptoms and signs and health-related quality of life in the unstable angina patients with blood-stasis syndrome after percutaneous coronary intervention: A Randomized controlled trial[J]. Chinese Journal of Integrative Medicine, 2010,16(5):399-405.
Chu, Fy., Wang, J., Yao, Kw. et al. Effect of Xuefu Zhuyu Capsule (血府逐瘀胶囊) on the symptoms and signs and health-related quality of life in the unstable angina patients with blood-stasis syndrome after percutaneous coronary intervention: A Randomized controlled trial., Chin. J. Integr. Med. 16, 399–405 (2010). https://doi.org/10.1007/s11655-010-9999-9 DOI：

Fu-yong Chu, Jie Wang, Kui-wu Yao, et al. Effect of Xuefu Zhuyu Capsule (血府逐瘀胶囊) on the symptoms and signs and health-related quality of life in the unstable angina patients with blood-stasis syndrome after percutaneous coronary intervention: A Randomized controlled trial[J]. Chinese Journal of Integrative Medicine, 2010,16(5):399-405. DOI： 10.1007/s11655-010-9999-9.

摘要

Compared with Shengmai Capsule (生脉胶囊

SM)

the study was conducted to evaluate the efficacy and safety of Xuefu Zhuyu Capsule (血府逐瘀胶囊

XFZY) on the symptoms and signs and health-related quality of life (HR-QOL) in the unstable angina (UA) patients with blood-stasis syndrome (BSS) after percutaneous coronary intervention (PCI). A randomized

double-blinded

double-dummy

and placebo-controlled trial was applied. Ninety patients

diagnosed as UA and BSS after successful PCI

were enrolled and equally randomized into three groups

XFZY group

SM group

and placebo group

and administered with the corresponding medications respectively for four weeks. The clinical symptoms and signs (CSS)

electrocardiography (ECG)

and BSS scores were recorded and compared among groups during and after the treatment. Short-form 36 (SF-36) and Seattle Angina Questionnaire (SAQ) were applied to assess the HR-QOL in each group before and after the treatment. Safety indexes (blood routine and liver and kidney function tests) were also examined at the beginning and after the treatment. Eighty-six patients completed the whole study. After the treatment

the total effective rates of the XFZY group in ameliorating CSS and ECG were 76.7% and 60.0%

respectively

which were obviously higher than those in SM (CSS: 53.3%; ECG: 36.7%) and the placebo (CSS: 43.3%; ECG: 30.0%) groups. After one week’s treatment

BSS scores slightly decreased in each group

but no signifificant differences were found among three groups (P>0.05). After four weeks’ treatment

BSS scores in the XFZY group decreased to a lower level compared with SM (P <0.05) and the placebo (P <0.01) groups. After the treatment

the effificacy of XFZY group in improving body pain (BP)

general health (GH)

vitality (VT)

society functioning (SF)

role emotional (RE)

angina stability (AS)

angina frequency (AF)

and treatment satisfaction (TS) were better than those in the placebo group (P <0.05

P <0.01). Meanwhile

the dimensions of BP

and TS were better improved than those in the SM group P <0.05). No obvious adverse reaction was found during and after the treatment except one case in the XFZY group reporting of stomach discomfort. Compared with SM Capsule treatment

a short-term treatment with XFZY Capsule exhibits better effificacy on CSS and BSS scores

and HR-QOL in UA patients with BSS after PCI. However

its long-term effificacy and safety still needs further investigation.

Abstract

Compared with Shengmai Capsule (生脉胶囊

SM)

the study was conducted to evaluate the efficacy and safety of Xuefu Zhuyu Capsule (血府逐瘀胶囊

double-blinded

double-dummy

and placebo-controlled trial was applied. Ninety patients

diagnosed as UA and BSS after successful PCI

were enrolled and equally randomized into three groups

XFZY group

SM group

and placebo group

and administered with the corresponding medications respectively for four weeks. The clinical symptoms and signs (CSS)

electrocardiography (ECG)

the total effective rates of the XFZY group in ameliorating CSS and ECG were 76.7% and 60.0%

respectively

which were obviously higher than those in SM (CSS: 53.3%; ECG: 36.7%) and the placebo (CSS: 43.3%; ECG: 30.0%) groups. After one week’s treatment

BSS scores slightly decreased in each group

but no signifificant differences were found among three groups (P>0.05). After four weeks’ treatment

BSS scores in the XFZY group decreased to a lower level compared with SM (P <0.05) and the placebo (P <0.01) groups. After the treatment

the effificacy of XFZY group in improving body pain (BP)

general health (GH)

vitality (VT)

society functioning (SF)

role emotional (RE)

angina stability (AS)

angina frequency (AF)

and treatment satisfaction (TS) were better than those in the placebo group (P <0.05

P <0.01). Meanwhile

the dimensions of BP

a short-term treatment with XFZY Capsule exhibits better effificacy on CSS and BSS scores

and HR-QOL in UA patients with BSS after PCI. However

its long-term effificacy and safety still needs further investigation.

关键词

Xuefu Zhuyu CapsuleUnstable AnginaPercutaneous Coronary Interventiondouble-blinddouble-dummy

Keywords

Xuefu Zhuyu CapsuleUnstable AnginaPercutaneous Coronary Interventiondouble-blinddouble-dummy

references

Yeghiazarians Y, Braunstein JB, Askari A, Stone PH. Unstable angina pectoris. N Engl J Med 2000;342:101–114.

Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, Nallamothu BK, Kent DM. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. Lancet 2009;373:911–918.

Marzocchi A, Saia F, Piovaccari G, Manari A, Aurier E, Benassi A, et al. Long-term safety and efficacy of drugeluting stents: two-year results of the REAL (REgistro AngiopLastiche dell’ Emilia Romagna) multicenter registry. Circulation 2007;115:3181–3188.

Fattori R, Piva T. Drug-eluting stents in vascular intervention. Lancet 2003;361:247–249.

van Werkum JW, Heestermans AA, de Korte FI, Kelder JC, Suttorp MJ, Rensing BJ, et al. Long-term clinical outcome after a first angiographically confirmed coronary stent thrombosis: an analysis of 431 cases. Circulation 2009;119:828–834.

Bliley AV, Ferrans CE. Quality of life after coronary angioplasty. Heart Lung 1993; 22:193–199.

Holubkov R, Laskey WK, Haviland A, Slater JC, Bourassa MG, Vlachos HA, et al. Angina 1 year after percutaneous coronary intervention: a report from the NHLBI Dynamic Registry. Am Heart J 2002; 144:826–833.

Cronin SN, Freeman LH, Ryan G, Drake DM. Recovery after percutaneous transluminal coronary angioplasty: Assessment after discharge. Critical Care Nurse 2000;20:70–76.

Kimble LP, King KB. Perceived side effects and benefits of coronary angioplasty in the early recovery period. Heart Lung 1998;27:308–314.

Barnason SA, Zimmerman LM, Brey B, Catlin S, Nieveen JL. Patterns of recovery following percutaneous coronary intervention: a pilot study. Appl Nurs Res 2006;19: 31–37.

Pedersena SS, Denolleta J, Daemen J, van de Sande M, de Jaegere PT, Serruys PW, et al. Fatigue, depressive symptoms, and hopelessness as predictors of adverse clinical events following percutaneous coronary intervention with paclitaxel eluting stents. J Psychosom Res 2007;62: 455–461.

Zheng GL, Wang SH. Clinical effect and mechanism of Xuefu Zhuyu Capsule in treating unstable angina pectoris. Chin J Integr Tradit West Med (Chin) 2009;29:65–68.

Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA 2002 guideline update for management of patients with unstable angina and non-ST-segment elevation myocardial infarction summary article. J Am Coll Cardiol 2002; 40:1366–1374.

Specialty Committee of Activating Blood Circulation and Removing Blood Stasis of Research, Chinese Association of the Integrative Medicine. Diagnostic criteria of bloodstasis syndrome. Chin J Integr Tradit West Med (Chin) 1987;7:cover 2.

Zheng XY, ed. Guiding principle of clinical research on new drugs of traditional Chinese medicine. Beijing: China Medic-Pharmaceutical Sciences and Technology Publishing House; 2002:69–73.

Li J, Zhang MZ, Chen BJ, Wang L, Ling XZ, Zhang XW, et al. Effect of Tongguan Capsule (通冠胶囊) on postintervention patients of coronary heart disease with qideficieney and blood stasis syndrome. Chin J Integr Tradit West Med (Chin) 2008;28:32–35.

Ware JE. SF-36 health survey mannual and interpretation guide. Boston. MA: The Health Institute; 1993:2–7.

Spertus JA, Winder JA, Dewhurst TA, Deyo RA, Fihn SD. Monitoring the quality of life in patients with coronary artery disease. Am J Cardiol 1994; 74:1240–1244.

Xu J, Hu YM, Yang YB, Wang BH, Xie YN. Health measurement questionnaire SF-36. Chin J Behav Med Sci (Chin) 1999;8:150–153.

Yin H, Zhang J, Lin H, Qiao Y, Wang R, Lu H, et al. Effect of traditional Chinese medicine Shu-mai-tang on angiogenesis, arteriogenesis and cardiac function in rats with myocardial ischemia. Phytother Res 2009;23:92–98

Cheng TO. Cardiovascular effects of Danshen. Int J Cardiol 2007;121:9–22.

Parmar HS, Kar A. Antiperoxidative, antithyroidal, antihyperglycemic and cardioprotective role of Citrus sinensis peel extract in male mice. Phytother Res 2008;22:791–795.

Wu YZ, Li SQ, Zu XG, Du J, Wang FF. Ginkgo biloba extract improves coronary artery circulation in patients with coronary artery disease: contribution of plasma nitric oxide and endothelin-1. Phytother Res 2008;22:734–739.

Ling H, Wu L, Li L. Corydalis yanhusuo rhizoma extract reduces infarct size and improves heart function during myocardial ischemia/reperfusion by inhibiting apoptosis in rats. Phytother Res 2006;20:448–453.

Liu YF, Yu HM, Zhang C, Yang RX, Yan FF, Liu Y, et al. Effects of Quyu Xiaoban capsules on Clinical outcomes and platelet activation and aggregation in patients with unstable angina pectoris. J Altern Complement Med 2007;13:571–576.

Tam WY, Chook P, Qiao M, Chan LT, Chan TY, Poon YK, et al. The efficacy and tolerability of adjunctive alternative herbal medicine (Salvia miltiorrhiza and Pueraria lobata) on vascular function and structure in coronary patients. J Altern Complement Med 2009;15:415–421.

Zhao J, Huang X, Tang W, Ren P, Xing Z, Tian X, et al. Effect of oriental herbal prescription Guan-Xin-Er-Hao on coronary flow in healthy volunteers and antiapoptosis on myocardial ischemia reperfusion in rat models. Phytother Res 2007;21:926–931.

Li CY. Progress of the study on blood stasis syndrome and prescriptions and medicinal herbs for activating blood circulation to eliminate stasis. Chin J Integr Tradit West Med (Chin) 1988; 5:317–320.

Jiang WY. Therapeutic wisdom in traditional Chinese medicine: a perspective from modern science. Trends Pharmacol Sci 2005;26:557–563.

Liang ZJ. Research on the scientific basisi of bloodstasis pattern. In: Chen KJ ed. Research on the bloodstasis pattern and activating blood circulation to remove blood-stasis. Shanghai: Shanghai Scientific and Technical Publishers; 1990:368–488.

Liu TX, Kong SP, Liao ZY, Lu SK. Assessment study on physical function and the quality of life for CHD patients with SAQ. Chin J Behav Med Sci (Chin) 1997;6:127–129.

FULL TEXT LINK

More>

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Clinical effect of Maixuekang Capsule (脉血康胶囊) on long-term prognosis in patients with acute coronary syndrome after percutaneous coronary intervention

Summary of 2011 Integrative Medical Doctors Conference

Protective effect of Chinese herbs for supplementing qi, nourishing yin and activating blood circulation on heart function of patients with acute coronary syndrome after percutaneous coronary intervention

Blood stasis syndrome and its treatment with activating blood circulation to remove blood stasis therapy

A multi-center randomized double-blind placebo-controlled trial of Xiongshao Capsule (芎芍胶囊) in preventing restenosis after percutaneous coronary intervention: A subgroup analysis of senile patients